Joseph Group Capital Management increased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 11.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,464 shares of the medical research company’s stock after buying an additional 782 shares during the quarter. Amgen comprises approximately 1.2% of Joseph Group Capital Management’s portfolio, making the stock its 24th largest position. Joseph Group Capital Management’s holdings in Amgen were worth $2,332,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Strategic Financial Concepts LLC purchased a new stake in Amgen in the second quarter valued at $26,000. Horizon Financial Services LLC purchased a new stake in Amgen in the 1st quarter valued at about $28,000. United Community Bank acquired a new position in Amgen in the fourth quarter valued at about $29,000. nVerses Capital LLC purchased a new position in Amgen during the second quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen during the second quarter valued at about $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Stock Performance
Shares of AMGN stock opened at $335.95 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85. The stock has a 50 day simple moving average of $329.44 and a 200-day simple moving average of $305.22. The company has a market cap of $180.22 billion, a price-to-earnings ratio of 47.99, a price-to-earnings-growth ratio of 2.93 and a beta of 0.61.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.68%. Amgen’s dividend payout ratio (DPR) is 128.57%.
Analyst Ratings Changes
Several equities analysts have recently commented on AMGN shares. TD Cowen upped their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Morgan Stanley lowered their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Dbs Bank raised Amgen to a “strong-buy” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Finally, Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $327.28.
Check Out Our Latest Analysis on AMGN
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Comparing and Trading High PE Ratio Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Plot Fibonacci Price Inflection Levels
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.